论文部分内容阅读
目的观察氨氯地平片联合倍他乐克对中青年原发性高血压病的降压效果及安全性。方法将1、2级中青年原发性高血压患者148例随机分成氨氯地平联合倍他乐克组(A组,n=50)、氨氯地平组(B组,n=49)、倍他乐克组(C组,n=49)3组。氨氯地平联合倍他乐克组(A组)50例患者服用氨氯地平片5～10mg,每日1次,倍他乐克12.5～25mg,每日2次;氨氯地平组(B组)49例患者单用氨氯地平片10～20mg,每日1次;倍他乐克组(C组)49例患者单用倍他乐克25～50mg,每日2次;均随访8周,观察3组降压效果,对心率的影响及不良反应发生率。结果氨氯地平联合倍他乐克组降压有效率及不良反应发生率分别为96.0%、16.0%,氨氯地平组为93.9%、28.6%,倍他乐克组为81.6%、22.4%。氨氯地平联合倍他乐克组(A组)、氨氯地平组(B组)两组间有效率比较差异无统计学意义(P>0.05);联合治疗组(A组)与倍他乐克组(C组)比较差异有统计学意义(P<0.05),氨氯地平组(B组)与倍他乐克组(C组)比较差异无统计学意义(P>0.05)。结论氨氯地平片联合倍他乐克有协同降压作用,适用于中青年高血压的治疗,值得临床推广应用。
Objective To observe the antihypertensive efficacy and safety of amlodipine combined with Betaloc on essential hypertension in middle-aged and young adults. Methods One hundred and eighty-eight middle-aged and young patients with essential hypertension were randomly divided into amlodipine and metoprolol group (group A, n = 50), amlodipine group (group B, n = 49) He Leke group (C group, n = 49) 3 groups. Amlodipine combined with Betaloc group (A group) 50 patients taking amlodipine tablets 5 ~ 10mg, 1 times daily, Betaloc 12.5 ~ 25mg, 2 times a day; amlodipine group (B group ) 49 cases of patients with amlodipine tablets 10 ~ 20mg, 1 times a day; Betaloc (49 cases of group C) methotrexate 25 ~ 50mg, 2 times a day; were followed up for 8 weeks , Observed three groups of antihypertensive effect, the impact on heart rate and the incidence of adverse reactions. Results The effective rates of Amlodipine and Betaloc were 96.0%, 16.0%, 93.9%, 28.6% for Amlodipine group and 81.6%, 22.4% for Betaloc group, respectively. Amlodipine combined with the Betaloc group (A group), amlodipine group (B group), there was no significant difference between the two groups (P> 0.05); combination therapy group (A group) (P <0.05). There was no significant difference between Amlodipine group (B) and Betaloc (C) group (P> 0.05). Conclusion Amlodipine combined with Betaloc has a synergistic antihypertensive effect and is suitable for the treatment of middle-aged and young patients with hypertension. It is worthy of clinical application.